CSB-321
Oncology (Immunotherapy monitoring)
Key Facts
About Cytosite Bio
Cytosite Bio is a private, pre-revenue biotech founded in 2018 and based in San Diego, CA. The company's core innovation is a proprietary platform targeting granzyme B, which it leverages for two main applications: a PET imaging diagnostic (CSB-321) to provide early, mechanistic readouts of immunotherapy efficacy, and a preclinical radioimmunotherapy (CSB-421) designed to deliver radiation directly to immunologically active tumor sites. This dual-pronged strategy seeks to de-risk drug development and address a critical unmet need in treating immunotherapy-resistant cancers. The company is currently in the clinical stage with its diagnostic candidate and advancing its therapeutic through preclinical studies.
View full company profile